{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"Establish the safety and tolerability of Pomalidomide and Dexamethasone in combination with MK-3475","groups":[{"description":"Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).\n\nMK-3475: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.\n\nPomalidomide: Pomalidomide is given at standard dose of 4 mg daily orally for 21 days\n\nDexamethasone: Dexamethasone is given at 40 mg orally weekly","id":"OG000","title":"Pomalidomide, Dexamethasone & MK-3475"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"24 month","title":"The Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}